Welcome to our dedicated page for Personalis news (Ticker: PSNL), a resource for investors and traders seeking the latest updates and insights on Personalis stock.
Personalis, Inc. (NASDAQ: PSNL) is a Fremont, California-based medical laboratories company focused on advanced genomics for precision oncology. The Personalis news stream centers on developments in molecular residual disease (MRD) testing, circulating tumor DNA (ctDNA) analysis, and ultra-comprehensive genomic profiling for cancer management.
News about Personalis often highlights clinical and scientific milestones for its NeXT Personal MRD platform, including publications in journals such as Clinical Cancer Research, Cell, Nature Medicine, and Annals of Oncology as referenced in company communications. These articles describe how NeXT Personal is used to detect very small traces of ctDNA, monitor treatment response, and predict outcomes across solid tumors, including breast cancer and non-small cell lung cancer.
Investors and clinicians following PSNL can expect updates on Medicare coverage decisions for NeXT Personal tests, reimbursement rate determinations, and coverage expansions for indications such as breast cancer surveillance. Press releases also cover collaborations with biopharma companies and academic centers, including trials like TRACERx, NeoADAURA, and LAURA, where Personalis’ assays are applied to assess residual disease, relapse risk, and therapy response.
Additional news items include quarterly and annual financial results, preliminary performance updates, and disclosures related to the company’s "Win-in-MRD" commercial strategy and clinical test volume trends. Corporate announcements such as participation in healthcare conferences, inducement equity grants under Nasdaq rules, and amendments to commercialization agreements with partners like Tempus AI, Inc. are also part of the PSNL news flow.
By reviewing Personalis news, readers can track how the company’s MRD and precision oncology platforms are being adopted in clinical practice and research, as well as monitor key regulatory, reimbursement, and partnership developments that shape its role in cancer genomics.
Personalis, Inc. (NASDAQ: PSNL) announced its relocation of corporate headquarters and Clinical Laboratory from Menlo Park to a new 100,000 sq. ft. facility in Fremont, aimed at supporting growth and expanding laboratory operations. The 13-year lease on the new facility, nearly doubling their existing space, reflects the company's ambition to enhance its presence in the cancer diagnostics market. CEO John West emphasized the intention to recruit top talent to meet business goals and strengthen R&D efforts. The move is expected to occur within the next 12 months.
Personalis, Inc. (Nasdaq: PSNL) reported record revenue of $21.7 million for Q2 2021, an 11% increase from $19.5 million in Q2 2020. The revenue from biopharma and other customers, excluding the VA MVP, grew 72% to $8.2 million. The company ended the quarter with cash and investments totaling $328.9 million. Despite achieving growth, Personalis faced a net loss of $15 million and an anticipated net loss of $65 million to $70 million for 2021. Looking ahead, Q3 revenue is expected to be around $22.2 million.
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced cancer genomics, announced its participation in the 6th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference on August 17, 2021. The company specializes in population sequencing and cancer genomics, focusing on providing comprehensive molecular data from a single tissue sample through the Personalis® ImmunoID NeXT Platform®. Additionally, Personalis is the sole sequencing provider to the VA MVP, emphasizing its commitment to quality and efficiency in oncology.
Personalis, Inc. (Nasdaq: PSNL) announced a study published in Clinical Cancer Research detailing the Personalis Neoantigen Presentation Score (NEOPS™), a new biomarker for predicting immunotherapy response in advanced melanoma patients. NEOPS, developed through extensive tumor profiling, outperformed traditional biomarkers like tumor mutational burden. The study involved late-stage melanoma patients and highlighted NEOPS's potential to enhance precision oncology. Personalis aims to utilize NEOPS for broader clinical applications, contributing to advancements in cancer screening and treatment.
Personalis, Inc. (Nasdaq: PSNL) will announce its Q2 2021 financial results on August 4, 2021, after market close. A conference call is scheduled for the same day at 2:00 PM PT / 5:00 PM ET to discuss the results and recent developments. Interested parties can join the live call via phone or access the webcast through the company's investor relations website. Personalis is recognized for its advancements in cancer genomics and population sequencing, operating a significant global sequencing operation while serving the VA MVP.
Personalis, Inc. (Nasdaq: PSNL) announced the NeXT Level Biomarkers Symposium, showcasing innovative research in cancer genomics, particularly through their NeXT Platform. The event will feature presentations on HLA loss of heterozygosity, neoantigen prediction, and the Neoantigen Presentation Score (NEOPS). Additionally, a case study from the Parker Institute for Cancer Immunotherapy will be highlighted. Richard Chen, CSO, expressed excitement about sharing advancements aimed at precision oncology. Further details and registration are available on their official website.
Summary not available.
Personalis, Inc. (Nasdaq: PSNL), a leader in cancer genomics, will participate in the Oppenheimer MedTech, Tools & Diagnostics Summit on May 26, 2021. This event will showcase the company’s advancements in population sequencing and the ImmunoID NeXT Platform, which offers comprehensive molecular data on cancer and immune response. The presentation will be available for 90 days on Personalis’ website, emphasizing their role as the sole sequencing provider for the U.S. Department of Veterans Affairs Million Veterans Program.
Personalis, Inc. (Nasdaq: PSNL) will present at Biomarkers Week Online 2021, showcasing the ImmunoID NeXT Platform for cancer immunogenomics. Erin Newburn, MS, PhD, will detail its capability to analyze tumor and immune microenvironment from a single sample. A case study on 51 late-stage melanoma patients highlights the platform's effectiveness in predicting responses to checkpoint blockade. Personalis is a co-sponsor of the event and aims to discuss its innovations in cancer genomics.
Personalis, Inc. (Nasdaq: PSNL) reported a record revenue of $20.9 million for Q1 2021, marking a 9% increase from $19.2 million in Q1 2020. Revenue from biopharma and other customers surged 74% to $7.7 million. The company added $162 million from a public offering, ending the quarter with $353.4 million in cash and equivalents. Despite these gains, net loss rose to $12.4 million, consistent with a net loss per share of $0.29. Outlook for Q2 2021 anticipates revenues of approximately $21.3 million and a net loss of $16 million to $17 million.